SOUTH SAN FRANCISCO, Calif., Oct. 2, 2018 /PRNewswire/ -- Senti Biosciences, the leading synthetic biology company developing next-generation adaptive therapies, today announced that it has been named by FierceBiotech as one of 2018's Fierce 15 biotechnology companies, designating it as one of the most promising companies in the industry.
Senti designs synthetic gene circuits for adaptive cell and gene therapies to enable medicines that respond dynamically to different states of disease. By programming sophisticated capabilities directly into living cells, Senti is developing therapies that can be controlled once administered, targeted to sites of disease, and trigger multifactorial responses based on disease severity. Senti is currently advancing several internal cell therapy programs toward the clinic in oncology indications.
"We are incredibly proud to be selected for this year's Fierce 15 and to stand alongside these other pioneering companies," said Tim Lu, CEO of Senti Biosciences. "At Senti, we believe that adaptive therapies have the potential to change the way we treat disease, and this award provides important validation of our unique platform and approaches."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's 16th annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Senti Biosciences
Senti Biosciences is a synthetic biology company pioneering adaptive cell and gene therapies to treat the most complex and challenging diseases. Using its synthetic biology technology platform, Senti designs synthetic gene circuits capable of responding dynamically to different disease states and biological settings. The company is developing an internal pipeline of therapeutic programs in oncology, and is pursuing partnerships for additional applications using its technology. Senti Biosciences is based in San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among their investors. For more information on Senti Biosciences, please visit https://www.sentibio.com/.
CONTACTS:
Jonathon O'Leary
Senti Biosciences PR
929-341-0421
[email protected]
SOURCE Senti Biosciences
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article